Breaking Finance News

Raymond James disclosed Voyager Therapeutics Inc (NDAQ:VYGR), boosting its price target to $35.00 earlier today

Reporting a possible upside of 0.42%, Raymond James raised the target price of Voyager Therapeutics Inc (NDAQ:VYGR) to $35.00

On Thursday August 17, 2017, Evercore ISI released a statement on Voyager Therapeutics Inc (NDAQ:VYGR) upped the target price from $0.00 to $12.00 that suggested an upside of 0.40%.

Having a price of $24.73, Voyager Therapeutics Inc (NDAQ:VYGR) traded 5.25% higher on the day. With the last close up 122.51% from the two hundred day average, compared with the Standard & Poor's 500 Index which has increased 0.03% over the same period. VYGR has recorded a 50-day average of $15.89 and a two hundred day average of $11.35. Trade Volume was up over the average, with 426,548 shares of VYGR changing hands over the typical 275,054

Recent Performance Chart

Voyager Therapeutics Inc (NDAQ:VYGR)

Voyager Therapeutics Inc has with a one year low of $8.10 and a one year high of $25.75 and has a market capitalization of $0.

A total of 3 analysts have released a report on Voyager Therapeutics Inc. zero analysts rating the company a strong buy, zero analysts rating the company a buy, zero analysts rating the company a hold, zero analysts rating the company a underperform, and finally zero analysts rating the company a sell with a 12-month price target of $28.00.

General Company Details For Voyager Therapeutics Inc (NDAQ:VYGR)

Voyager Therapeutics, Inc. is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company's pipeline consists of programs for CNS indications, including advanced Parkinson's disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington's disease; Friedreich's ataxia; frontotemporal dementia/Alzheimer's disease, and severe chronic pain. The Company's clinical candidate, VY-AADC01, is an adeno-associated virus (AAV) gene therapy product candidate, for the treatment of advanced Parkinson's disease. VY-AADC01 consists of the AAV2 capsid, which has been used in multiple AAV gene therapy clinical trials for various diseases, and the cytomegalovirus promoter that drives expression of the aromatic L-amino acid decarboxylase (AADC) transgene. Its pipeline also includes VY-SOD101, VY-FXN01, VY-HTT01, VY-TAU01 and VY-NAV01.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.